FindTrial
Sign In

Lipiodol-based clinical efficacy prediction strategy for TACE therapy in hepatocellular carcinoma

Evaluation of the Lipiodol-based clinical efficacy prediction strategy for TACE in patients with hepatocellular carcinoma

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016851
Enrollment
Unknown
Registered
2018-06-28
Start date
2018-07-21
Completion date
Unknown
Last updated
2018-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

LCEPS:LCEPS-suggested TACE therapy
non-LCEPS:Interventional physician-suggested TACE therapy

Sponsors

Jiangdian Song
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria required that patients had CT and/or MR scans at one month after TACE therapy for lipiodol deposition evaluation, age older than 20 years, periodically follow-up and preoperative baseline information. Patients who eligible for this experiment were required to perform contrast-enhanced CT scans in two weeks before TACE start.

Exclusion criteria

Exclusion criteria: Those patients with complication of intrahepatic hemorrhage (or other sites) after TACE, or received other therapy as the first treatment, or poor quality of CT or MR resulting in failing evaluation of LD were excluded in this study.

Design outcomes

Primary

MeasureTime frame
time to progression;—

Countries

China

Contacts

Public ContactJiangdian Song

China Medical University

jdsong@cmu.edu.cn+86 13324032368

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026